Vir Biotechnology, GSK Terminate Collaboration on Flu
By Denny Jacob
Vir Biotechnology and GSK terminated their collaboration regarding the flu.
The clinical-stage immunology company and GSK collaborated to research, develop and commercialize Vir's monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus under an agreement established in May 2021.
Vir said the change reflects that it retains sole rights to continue advancing its investigational therapies for influenza independently or with other partners. The company added that it's actively pursuing external partnership opportunities for its next-generation influenza A and B antibodies and antibody drug conjugates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 22, 2024 16:57 ET (21:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now